## Paula Tabares

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7372708/publications.pdf

Version: 2024-02-01

40 papers

2,292 citations

304743

22

h-index

330143 37 g-index

40 all docs

40 docs citations

times ranked

40

2725 citing authors

#	Article	IF	CITATIONS
1	TLR signals license CD8 TÂcells to destroy oligodendrocytes expressing an antigen shared with a <i>Listeria</i> pathogen. European Journal of Immunology, 2019, 49, 413-427.	2.9	5
2	TNFRSF receptor-specific antibody fusion proteins with targeting controlled Fcl <sup>3</sup> R-independent agonistic activity. Cell Death and Disease, 2019, 10, 224.	6.3	26
3	Shortâ€ŧerm cytokine stimulation reveals regulatory TÂcells with downâ€regulated Foxp3 expression in human peripheral blood. European Journal of Immunology, 2018, 48, 366-379.	2.9	11
4	The secreted Candida albicans protein Pra1 disrupts host defense by broadly targeting and blocking complement C3 and C3 activation fragments. Molecular Immunology, 2018, 93, 266-277.	2.2	34
5	Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation. Frontiers in Immunology, 2018, 8, 1985.	4.8	6
6	CD28 Costimulation of T Helper 1 Cells Enhances Cytokine Release In Vivo. Frontiers in Immunology, 2018, 9, 1060.	4.8	11
7	Targeting of the WT191–138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination. Cancer Immunology, Immunotherapy, 2017, 66, 319-332.	4.2	10
8	Protection of Mice from Acute Graft-versus-Host Disease Requires CD28 Co-stimulation on Donor CD4+ Foxp3+ Regulatory T Cells. Frontiers in Immunology, 2017, 8, 721.	4.8	1
9	The rise and fall of the <scp>CD</scp> 28 superagonist <scp>TGN</scp> 1412 and its return as <scp>TAB</scp> 08: a personal account. FEBS Journal, 2016, 283, 3325-3334.	4.7	41
10	In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice. European Journal of Immunology, 2016, 46, 1193-1202.	2.9	10
11	Interrupting CD28 costimulation before antigen rechallenge affects CD8 <sup>+</sup> T ell expansion and effector functions during secondary response in mice. European Journal of Immunology, 2016, 46, 1644-1655.	2.9	18
12	Boost of Immune Responses Against NY-ESO-1 Following Local Radiation Therapy in Patients with Multiple Myeloma: A Potential Contribution to Tumor Immunosurveillance. Blood, 2016, 128, 4512-4512.	1.4	0
13	High-density preculture of PBMCs restores defective sensitivity of circulating CD8 T cells to virusand tumor-derived antigens. Blood, 2015, 126, 185-194.	1.4	28
14	In vitro polyclonal activation of conventional TÂcells with a CD28 superagonist protects mice from acute graft versus host disease. European Journal of Immunology, 2015, 45, 1997-2007.	2.9	8
15	CD28 co-stimulation in T-cell homeostasis: a recent perspective. ImmunoTargets and Therapy, 2015, 4, 111.	5.8	97
16	The T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis. Journal of Neuroimmunology, 2015, 282, 63-72.	2.3	8
17	Amplification of Regulatory T Cells Using a CD28 Superagonist Reduces Brain Damage After Ischemic Stroke in Mice. Stroke, 2015, 46, 212-220.	2.0	94
18	Novel Receptor-Derived Cyclopeptides to Treat Heart Failure Caused by Anti- $\hat{l}^2$ 1-Adrenoceptor Antibodies in a Human-Analogous Rat Model. PLoS ONE, 2015, 10, e0117589.	2.5	20

#	Article	IF	CITATIONS
19	Human regulatory TÂcells are selectively activated by lowâ€dose application of the CD28 superagonist TGN1412/TAB08. European Journal of Immunology, 2014, 44, 1225-1236.	2.9	84
20	Eberhard Wecker (1923–2013). European Journal of Immunology, 2013, 43, 1986-1987.	2.9	0
21	Oligodendrocytes Enforce Immune Tolerance of the Uninfected Brain by Purging the Peripheral Repertoire of Autoreactive CD8+ T Cells. Immunity, 2012, 37, 134-146.	14.3	32
22	CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation. Medical Microbiology and Immunology, 2010, 199, 239-246.	4.8	23
23	Na $\tilde{A}$ ve CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain, 2008, 131, 2353-2365.	7.6	79
24	Manipulation of Regulatory Tâ€Cell Number and Function with CD28â€Specific Monoclonal Antibodies. Advances in Immunology, 2007, 95, 111-148.	2.2	48
25	Induction of experimental autoimmune encephalomyelitis in transgenic mice expressing ovalbumin in oligodendrocytes. European Journal of Immunology, 2006, 36, 207-215.	2.9	40
26	IL-2 and autoimmune disease. Cytokine and Growth Factor Reviews, 2002, 13, 369-378.	7.2	87
27	Thymic development and repertoire selection: the rat perspective. Immunological Reviews, 2001, 184, 7-19.	6.0	22
28	Control of T cell hyperactivation in IL-2-deficient mice by CD4+CD25- and CD4+CD25+ T cells: evidence for two distinct regulatory mechanisms. European Journal of Immunology, 2001, 31, 1637-1645.	2.9	160
29	Autonomous induction of proliferation, JNK and NF-κB activation in primary resting T cells by mobilized CD28. European Journal of Immunology, 2000, 30, 876-882.	2.9	30
30	Autonomous induction of proliferation, JNK and NF-κB activation in primary resting T cells by mobilized CD28., 2000, 30, 876.		1
31	CD28â€mediated induction of proliferation in resting T cells ⟨i⟩in vitro⟨ i⟩ and ⟨i⟩in vivo⟨ i⟩ without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28. European Journal of Immunology, 1997, 27, 239-247.	2.9	153
32	Orally induced, peptide-specific $\hat{l}^3/\hat{l}$ TCR+ cells suppress experimental autoimmune uveitis. European Journal of Immunology, 1996, 26, 2140-2148.	2.9	77
33	Identification and cellular distribution of the rat interleukin-2 receptor β chain: induction of the IL-2Rαâ^î²²+ phenotype by major histocompatibility complex class I recognition during T cell developmentin vivo and by T cell receptor stimulation of CD4+8+ immature thymocytesin vitro. European Journal of Immunology, 1996, 26, 2371-2375.	2.9	8
34	The canonical T cell receptor of dendritic epidermal $\hat{I}^{\hat{J}}$ T cells is highly conserved between rats and mice. European Journal of Immunology, 1996, 26, 3092-3097.	2.9	26
35	Impaired survival of T cell receptor $\hat{V^{3}}$ 3+ cells in interleukin-4 transgenic mice. European Journal of Immunology, 1995, 25, 1442-1445.	2.9	13
36	Prevention and treatment of Lewis rat experimental allergic encephalomyelitis with a monoclonal antibody to the T cell receptor $\hat{V}^2$ 8.2 segment. European Journal of Immunology, 1995, 25, 1960-1964.	2.9	32

3

#	Article	IF	CITATION
37	Characterization of mouse CD53: Epitope mapping, cellular distribution and induction by T cell receptor engagement during repertoire selection. European Journal of Immunology, 1995, 25, 2201-2205.	2.9	31
38	Thymic selection and peptide-induced activation of T cell receptor-transgenic CD8 T cells in interleukin-2-deficient mice. European Journal of Immunology, 1994, 24, 2317-2322.	2.9	58
39	Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature, 1991, 352, 621-624.	27.8	836
40	Induction of proliferative and cytotoxic responses in resting Lyt-2+ T cells with lectin and recombinant interleukin 2. European Journal of Immunology, 1985, 15, 332-337.	2.9	24